文献速递妇科

晚期卵巢癌新辅助化疗反应相关因素分析

Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-04-07

该回顾性研究纳入562例晚期卵巢癌患者,按分诊算法接受新辅助化疗(NACT)。413例(74%)行间歇性肿瘤减灭术(iTRS)。iTRS时CA-125≤35 U/mL与完全肉眼切除率更高(88% vs 65%)及PFS改善(16.8 vs 12.7个月)相关。剂量密集紫杉醇和CA-125正常化与更高影像学完全缓解率相关。多因素分析显示胚系BRCA1/2突变、iTRS(R0/≤1cm/>1cm)、剂量密集化疗及iTRS时CA-125≤35 U/mL是PFS的独立影响因素。

要点

  • iTRS时CA-125≤35 U/mL与更高完全肉眼切除率和改善的PFS相关
  • 剂量密集紫杉醇较常规剂量提高缓解率和PFS
  • 胚系BRCA1/2突变、iTRS切除程度、剂量密集化疗和CA-125正常化是PFS独立影响因素

核心结论

  • NACT后iTRS时CA-125正常化可作为该高危人群的预后替代标志物
  • 剂量密集方案较常规剂量提高缓解率和PFS

研究设计与样本

  • 回顾性研究,2013年4月至2019年3月,562例晚期卵巢癌患者按标准分诊算法接受NACT
  • 132例经腹腔镜评估,430例未行腹腔镜

主要发现

  • 413例(74%)接受iTRS
  • 与达到iTRS相关的因素包括年龄增加(p<0.001)、Charlson合并症指数更高(p<0.001)、ECOG状态2或3(p<0.001)及腹腔镜评估(p<0.001)
  • iTRS时CA-125≤35 U/mL者完全肉眼切除率更高(88% vs 65%,p<0.001),PFS更优(16.8 vs 12.7个月,p<0.001)
  • 接受剂量密集紫杉醇者影像学完全缓解率更高(76% vs 60%,p=0.004),iTRS时CA-125≤35 U/mL者更高(85% vs 66%,p<0.001)
  • 多因素分析中,胚系BRCA1/2突变(p=0.001)、iTRS对比未手术(R0 p<0.001;≤1cm p<0.001;>1cm p<0.001)、剂量密集化疗(p=0.01)及iTRS时CA-125≤35 U/mL(p=0.001)为PFS的独立显著影响因素

临床怎么用

  • NACT后iTRS前检测CA-125,若≤35 U/mL提示预后较好,可辅助临床决策
  • 对适合患者可考虑剂量密集紫杉醇方案以改善缓解率和PFS
  • 关注年龄、合并症指数、ECOG状态及腹腔镜评估对达到iTRS的影响

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the factors associated with response to neoadjuvant chemotherapy (NACT) and the ability to undergo interval tumor reductive surgery (iTRS) in patients with advanced ovarian cancer. METHODS: We performed a retrospective review from April 2013 to March 2019 of patients with advanced stage ovarian cancer triaged to NACT based on our standard triage algorithm. Clinicopathologic and treatment data were analyzed for factors associated with response to NACT, outcomes at iTRS, and their impact on progression-free survival (PFS). RESULTS: 562 patients met inclusion criteria and triaged to NACT following laparoscopy (n = 132) or without laparoscopy (n = 430). 413 patients underwent iTRS (74%). Factors that correlated with a patient reaching iTRS included increasing age (p < 0.001), higher Charlson comorbidity index (p < 0.001), ECOG status 2 or 3 (<0.001), and laparoscopic assessment (<0.001). Patients with CA-125 ≤ 35 U/mL at iTRS had higher rates of complete gross resection (88% vs. 65%, p < 0.001) and improved PFS (16.8 vs. 12.7 months, p < 0.001). Patients receiving dose-dense paclitaxel (76% vs. 60%, p = 0.004) and CA-125 ≤ 35 U/mL at iTRS (85% vs. 66%, p < 0.001) had higher rates of complete radiographic response. On multivariate analysis, germline BRCA 1/2 mutation (p = 0.001), iTRS vs. no surgery (R0, p < 0.001; ≤1 cm, p < 0.001; >1 cm, p < 0.001), dose-dense chemotherapy (p = 0.01), and CA-125 ≤ 35 U/mL at iTRS (p = 0.001) were independent significant factors affecting PFS. CONCLUSIONS: Normalization of CA-125 at the time of iTRS following NACT may serve as a surrogate marker for prognosis in this high-risk population. Our NACT cohort experienced improved response rates and PFS with dose-dense therapy compared to conventional dosing.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fleming ND, Westin SN, Rauh-Hain JA, et al. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021. PMID: 33838925. doi:10.1016/j.ygyno.2021.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。